Substitut	te for i	form 1449A/PTO (Replic	ation)	Complete if Known		
		TION DISCLOSE		Application Number	10/661,329	
STAT	EME	NT BY APPLICA	NT	Filing Date	September 12, 2003	
E	/	(LE 108)		First Named Inventor	Allan L. Louderback	
		ש מונה		Art Unit		
		DET O 1 DATE THE		Examiner Name		
Sheet	Pi,	1	4	Attorney Docket Number	ALLO01	
		EIRADE	U.S. PATEN	T DOCUMENTS		
Examiner Initials	l t e m	Document Number  Number - kind code (if known)	Patent Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
An	01	4,305,871	12-15-81	Shanbrom	Abstract, Example 1, Claim 1	
m	02	4,314,997	02-09-82	Shanbrom	Abstract, First paragraph following Description of Invention, Claim 1	
~~	03	4,315,919	02-16-82	Shanbrom	Abstract, Claim 1	
M	04	4,412,985	11-01-83	Shanbrom	Abstract, Claim 1	
N	05	4,481,189	11-06-84	Prince	Abstract, See first paragraph of Discussion of Prior Art eighth paragraph of same section	
M	06	4,591,505	05-27-86	Prince	Abstract, Division of 4,481,189	
W	07	4,764,369	08-16-88	Neurath, et al.	See abstract, prior art discussion	
M	ОВ	4,833,165	05-23-89	Louderback	See Details of Invention, Claim	
N	09	4,909,940	03-20-90	Horowitz	Abstract, Background, Claim 1	
N	10	5,094,960	03-10-92	Bonomo	Abstract, Claim 1	
m	11	5,120,649	06-09-92	Horowitz, et al.	Abstract, Claim 1	
<b>/~~</b>	12	5,186,945	02-16-93	Shanbrom	See Abstract, Claim 1	
M	13	5,648,472	07-15-97	Gehringer, et al.	See Abstract, Claim 1	
W	14	6,372,216	04-16-02	Piazza	See Abstract, See last paragraph before claims	
M	15	6,468,733	10-22-02	Nur, et al.	See Abstract, Claim 1	
N	16	6,514,987	02-04-2003	Cook, et al.	See Abstract, Claim 1	

		FOREIGN PATENT	DOCUMENTS		
	None				
Examiner Signature		Sm	Date Considered	11/18/04	
	7	$ \wedge $		//	

Substitute	for fo	rm 1449A/PTC	(R	eplication)	Complete if Known			
1		TION DISC			Application Number	10/661,329		
STATE	STATEMENT BY APPLICANT				Filing Date	10/861,329		
\ \( \text{Q} \)	di Sign				First Named Inventor	Allan L. Louderback		
٠,	A SA				Art Unit			
1	,	<b>Ž</b>			Examiner Name			
Sheet	NT.8	IEA 2	o f	4	Attorney Docket Number	ALL001		
	. 4	OTHER	PR	IOR ART - NON PAT	ENT LITERATURE DOC	CUMENTS		
Examiner Initials	#			journal, serial, symposium, o	TERS), title of the article (when a catalog, etc.), date, page(s), volu or county where published			
Xh	01	AGER, A.; ANDERSON, SL; LOUDERBACK AL; MILHOUS, WK; Formaldehyde/Detergent Solution Prevents Blood Borne Transmission of [Plasmaodium] Infection in a Mouse Model, American Society of Tropical Medicine and Hygiene, Abstract Submission Form, Annual Meeting, 1991						
m	02	EHUD BEN-HUR, BERNARD HOROWITZ, Virus Inactivation in Blood, Editorial Review, AIDS 1996, 10:1183-1190, Rapid Science Publishers ISSN 0269-9370.						
M	03	CHEN, SX; HAMMOND, DJ; LANG, JM; LEBING, WR; Purification of $\alpha_1$ Protinase Inhibitor from Human Plasma Fraction IV-1 by Ion Exchange Chromatography; Vox Sanguinis, 1998: 74(4): 232-241.						
W	04	CHEN, SX; HAMMOND, DJ; KLOS, AM; WOOD, DW; WYDICK, JE; LEBING, WR; Chromatography Purification of human α, Proteinase Inhibitor from Dissolved Cohn Fraction IV-1 Paste; Journal of Chromatography A. 800 (2) (1998): 207-218.						
N	05	HIGHSMITH, F; XUE, H; CHEN, X; BENADE, L; OWENS, J; SHANBROM, E; DROHAN, W; lodine-mediated Inactivation of Lipid- and Nonlipid-enveloped Viruses in Human Antithrombin III Concentrate; <i>Blood</i> , Volume 86, No. 2 (July 18, 1995); pages 791-796						
M	06	HIGHSMITH, FA; XUE, H; CAPLE, M; WALTHALL, B; DROHAN, WN, SHANBROM, E; Inactivation of Lipid-Enveloped and Non-lipid-enveloped Model Viruses in Normal Human Plasma by Crosslinked Starch-iodine; Plasma Derivatives Department, Holland Laboratory, American Red Cross, Rockville, Maryland, and Irvine Scientific Incorporated, Santa Ana, California; received for publication Aug. 26, 1993, revised Nov. 16, 1993 and accepted Nov. 22, 1993; published in Transfusion, 1994; Volume 34, No. 4, pages 322-327.						
W	07	Vesicular Stor	HIGHSMITH, FA; CAPLE, M; WALTHALL, B; SHANBROM, E; DROHAN, WN; Viral Inactivation of Vesicular Stomatitis Virus in Normal Human Serum by Cross-Linked Polyvinylpyrrolidone; The Journal of Infectious Diseases, 1993;167:1027-33, published by The University of Chicago.					
M	08	treated Blood	Pro	ducts; <i>Blood Coagul. Fibr</i> i	WATKLEVICZ,C; Viral Safett inolysis. 1994 Dec; 5 Suppl 3 iral safety in formal clinical tri	2: S21-28. See Abstract		

Examiner Signature	agan	Date Considered	11/15/04	
			/ /	

Substitute	Substitute for form 1449A/PTO (Replication)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known			
					Application Number	10/661,329		
STATE					Filing Date	September 12, 2003		
					First Named Inventor	Allan L. Louderback		
1					Art Unit			
100					Examiner Name			
Sheet	NIB	TBAL3	of	4	Attorney Docket Number	ALL001		
		OTHE	R PRI	OR ART - NON PAT	ENT LITERATURE DOC	CUMENTS		
Examiner Initials	#	include na (book, mag	ame of pazine, j	journal, serial, symposium, i	TERS), title of the article (when catalog, etc.), date, page(s), volum county where published	appropriate, title of the item ume-issue numbers, publisher,		
m	_09	HOROWIT: proceeding	Z, B; P Is pape	athogen Inactivated Tra er from <i>Vox Sanguinis (V</i>	nsfusion Plasma: Existing and Fox Sang 2002: 83, (Suppl. 1	I Emerging Methods, a		
m	10	HOROWITZ Inactivation	HOROWITZ, B; BEN-HUR, E; Efforts in Minimizing Risk of Viral Transmission through Viral Inactivation; <i>The Finish Medical Society Duodecim, Ann. Med. 2000, 32: 475-484.</i>					
W	11	HOROWITZ, B; LAZO, A; GROSSBERG, H; PAGE, G; LIPPIN, A; SWAN, G.; Virus Inactivation by Solvent/Detergent Treatment and the Manufacture of SD-Plasma; Vox Sanguinis, Lunch Symposium Paper; Vox Sang. 1998, 74, Suppl. 1;: 203-206.						
m	12	HOROWITZ, B; PRINCE, AM; HAMMAN, J; WATKLEVICZ, C; Viral Safety of Solvent/Detergent-treated blood products - ABSTRACT; <i>Dev Biol Stand. 1993;81: 147-161.</i>						
W	13	KORNEYEYA, M; HOTTTA, J; LEBING, W; ROSENTHAL, RS; FRANKS, L; PETTEWAY, SR Jr.; Enveloped Virus Inactivation by Caprylate: a Robust Alternative to Solvent-Detergent Treatment in Plasma Derived Intermediates; <i>Biologicals</i> , 2002 Jun; 30(2): 153-62.						
W	14	LEBING, WR; HAMMOND, DJ; WYDICK, JE III; BAUMBACH, GA; A Highly Purified Antithrombin III Concentrate Prepared from Human Plasma Fraction IV-1 by Affinity Chromatography; Vox Sanguinis, Vox Sang., 1994; 67(2): 117-124.						
w	15	LEBING, W; REMINGTON, KM; SCHREINER, C; PAUL, I; Properties of a New Intravenous Immunoglobulin (IGIV-C, 10%) Produced by Virus Inactivation with Caprylate and Column Chromatography; copyright Blackwell Publishing, Ltd., Vox Sanguinis (2003): 84(3), 193-201.						
M	16	TERRY, JC; the Partition	LEE, DC; STENLAND, CJ; MILLER JLC; CAI, K; FORD, EK; GILLIGAN, KJ; HARTWELL, RC; TERRY, JC; RUBENSTEIN, R; FOURNEL, M; PETTEWAY SR Jr.; A Direct Relationship between the Partitioning of the Pathogenic Prion Protein and Transmissible Spongiform Encephalopathy Infectivity during the Purification of Plasma Proteins; <i>Transfusion</i> , 2001: 41(4): 449-455.					
M	,77	LOUDERBA 5 <sup>th</sup> National GA on Marc	Forum	on AIDS, Hepatitis and	ion of Blood for Transfusion; other Blood Borne Diseases;	Oral presentation at the CDC Meeting, Atlanta,		

Examiner Signature	Mun	Date Considered	11/18/04
	0		

Substitute	far for	m 1449A/P1	O (Re	plication)	Comple	te if Known
		ION DIS			Application Number	10/661,329
. =	STATEMENT BY APPLICANT				Filing Date	September 12, 2003
-					First Named Inventor	Allan L. Louderback
ដ្ឋ		Ž			Art Unit	
\	TENT	<b>9</b>			Examiner Name	
Sheet		4	of	4	Attorney Docket Number	ALL001
		OTHER	R PRI	OR ART - NON P	ATENT LITERATURE DOC	CUMENTS
Examiner Initials	#	include n (book, ma	ame of gazine,	journal, serial, symposi	L LETTERS), title of the article (when ium, catalog, etc.), date, page(s), voi and/or county where published	appropriate, title of the item lume-issue numbers, publisher
M	18	LOUDERB in San Fra	ACK,	A; Sterilization of Rep., November 11, 195	d Blood Cells for Transfusion; Sp 12.	eech at 45 <sup>th</sup> AABB Meeting
N	19	Immunogi	obulin	and Other Human Pl	, DC; Ensuring the Pathogen Safety of Intravenous sma-derived Therapeutic Proteins; Journal of Allergy 108, pages S91-4 (Figure S92).	
N	20	SCHUTZ, VIII Prepar	R; De ration,	velopment and Bioch	D; NUR, I; STRADLER, M; BAL, emical Characterization of a Dou nd Fibrinolysis, Vol 6, Suppl. 2, -47.	ble-virus-inactivated Factor
w	21	1 Deterge	nt Tre	ated, Pasteurised and	DJ; BAL, F; GEHRINGER, W; NU I Highly Purified Factor VIII Conc I pages 188-191 (English and Ge	entrate: Arzneim
W	22	Human an	d She	ep Forms of the Path	; PETTEWAY SR Jr.; RUBENSTE ogenic Prion Protein during the Pusion, Volume 42(11), November	urification of Theraneutic
n	23	Jr.; REMIN	IGTON Obulin	l, KM; Evaluation of \ Manufacturing Proce	STENLAND, C; STORMS, RE; LE Virus and Prion Reduction in a Ne ss; Vox Sanguinis (2003) 84, 17	ew Intravenous
N	24	PRINCE, A	M; Blo	ood Products; Nature.	. 1996 Jan 4; 379 (6560):14. S	ee entire article
m	25	STORMS,	RB; RI	JBENSTEIN, R; PETEI	GILLIGAN, KJ; HARTWELL, RC; WAY, SR Jr.; LEE, DC; Solvent-d ca Acta. 2002 May 20; 1597(1)	ependent Precinitation of

Examiner Signature	Soll	Date Considered	11/18/04	
	0 ()		//	